Tax is the drug again as US rival bids £27bn for Shire

 

Deputy Business editor

A second US drugs company has followed Pfizer in trying to buy a FTSE 100 giant in the hope of moving its tax base to Britain. AbbVie, until recently a division of Abbot Laboratories, has offered £27bn to buy Shire Pharmaceuticals, famed for its medicines for attention deficit disorder and rare diseases.

Shire moved to Ireland in 2008 to save tax but, just like Pfizer with AstraZeneca, AbbVie wants to merge its operations and move the domicile to the UK so it can benefit from Britain’s new-found tax- haven status.

The tax trick would not work if the combined group remained in Ireland, because US laws mean companies can only carry out such “inversion” deals with their tax domicile if at least a fifth of their shareholders are based in the new country.

UK corporate taxes are lower than in most developed economies, while patented products such as medicines carry further tax breaks.

Shire said it had rejected offers from AbbVie on 5 May, 13 May and 30 May, claiming they “fundamentally” undervalued its prospects. For the first time, it declared it would double sales to $10m (£6m) by 2020.

Shire says its fortunes have been transformed by its move into rare diseases, where sales of its medicines are running 39 per cent above last year.

AbbVie’s offer was priced at £46.11 per Shire share in cash and paper. Although based in Ireland now, Shire’s shares still trade on the London Stock Exchange.

While the takeover appears to have the hallmarks of the AstraZeneca takeover tussle, it does not have the same political ramifications.

Unlike AstraZeneca, Shire has no significant research and development presence in the UK, only employing about 400 staff in its Basingstoke head office. Its R&D scientists, who number about 1,700, are mostly in Massachusetts.

Nevertheless, AbbVie has hired the same political and media advisers as Pfizer used on its own bid – Sir Alan Parker’s Brunswick. Again like Pfizer, its panel of advisers include JPMorgan. Shire is using the banks Citi, Evercore and Morgan Stanley for its defence.

AbbVie’s blockbuster medicine is a treatment for rheumatoid arthritis called Humira, which is by some counts the biggest-selling medicine in the world. But this will begin losing its patent protection in the US and Europe in the next few years, and analysts said yesterday that Shire would provide AbbVie with the diversification it needs.

Shire’s share price leapt  17 per cent to 4,371p yesterday, and those close to the US company said it was considering a higher offer, possibly as early as next week.

At the latest price, the personal stake of Shire’s chief executive, Flemming Ornskov, would be worth £1m and his options would have a value of just under £2m.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Sales Assistant / Buyer

£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...

Recruitment Genius: Customer Service Advisor

£15000 - £16000 per annum: Recruitment Genius: Customer Service Advisors are r...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45K: SThree: SThree were established in 1986....

Recruitment Genius: Compliance Manager

£40000 - £60000 per annum: Recruitment Genius: A Compliance Manager is require...

Day In a Page

Greece debt crisis: What happened to democracy when it’s a case of 'Vote Yes or else'?

'The economic collapse has happened. What is at risk now is democracy...'

If it doesn’t work in Europe, how is it supposed to work in India or the Middle East, asks Robert Fisk
The science of swearing: What lies behind the use of four-letter words?

The science of swearing

What lies behind the use of four-letter words?
The Real Stories of Migrant Britain: Clive fled from Zimbabwe - now it won't have him back

The Real Stories of Migrant Britain

Clive fled from Zimbabwe - now it won’t have him back
Africa on the menu: Three foodie friends want to popularise dishes from the continent

Africa on the menu

Three foodie friends want to popularise dishes from the hot new continent
Donna Karan is stepping down after 30 years - so who will fill the DKNY creator's boots?

Who will fill Donna Karan's boots?

The designer is stepping down as Chief Designer of DKNY after 30 years. Alexander Fury looks back at the career of 'America's Chanel'
10 best statement lightbulbs

10 best statement lightbulbs

Dare to bare with some out-of-the-ordinary illumination
Wimbledon 2015: Heather Watson - 'I had Serena's poster on my wall – now I'm playing her'

Heather Watson: 'I had Serena's poster on my wall – now I'm playing her'

Briton pumped up for dream meeting with world No 1
Wimbledon 2015: Nick Bollettieri - It's time for big John Isner to produce the goods to go with his thumping serve

Nick Bollettieri's Wimbledon Files

It's time for big John Isner to produce the goods to go with his thumping serve
Dustin Brown: Who is the tennis player who knocked Rafael Nadal out of Wimbeldon 2015?

Dustin Brown

Who is the German player that knocked Nadal out of Wimbeldon 2015?
Ashes 2015: Damien Martyn - 'England are fired up again, just like in 2005...'

Damien Martyn: 'England are fired up again, just like in 2005...'

Australian veteran of that Ashes series, believes the hosts' may become unstoppable if they win the first Test
Tour de France 2015: Twins Simon and Adam Yates have a mountain to climb during Tour of duty

Twins have a mountain to climb during Tour of duty

Yates brothers will target the steepest sections in bid to win a stage in France
John Palmer: 'Goldfinger' of British crime was murdered, say police

Murder of the Brink’s-MAT mastermind

'Goldfinger' of British crime's life ended in a blaze of bullets, say police
Forget little green men - aliens will look like humans, says Cambridge University evolution expert

Forget little green men

Leading evolutionary biologist says aliens will look like humans
The Real Stories of Migrant Britain: An Algerian scientist adjusts to life working in a kebab shop

The Real Stories of Migrant Britain

An Algerian scientist struggles to adjust to her new life working in a Scottish kebab shop
Bodyworlds museum: Dr Gunther von Hagens has battled legal threats, Parkinson's disease, and the threat of bankruptcy

Dying dream of Doctor Death

Dr Gunther von Hagens has battled legal threats, Parkinson's disease, and the threat of bankruptcy